Evaluation of side-effects of dexmedetomidine depending on the volume of infusion during endoscopic submucosal dissection

Evaluation of side-effects of dexmedetomidine depending on the volume of infusion during endoscopic submucosal dissection - Side-effects of dexmedetomidine depending on the volume of infusion during ESD

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000033997

Enrollment

Registered

2018-09-03

Start date

2018-09-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neoplastic lesions of esophagus, stomach and colon

Interventions

1500ml infusion 1000ml infusion

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who undergo ESD (esophagus, stomach and colon) with using DEX

Exclusion criteria

Exclusion criteria: 1)uncontrollable diabetes 2)uncontrollable hypertension 3)uncontrollable heart disease 4)uncontrollable renal and/or urological diseases 5)hypovolemic 6)severe or uncontrollable respiratory disease 7)acute alcoholic addiction

Design outcomes

Primary

Measure	Time frame
Side-effects (hypotension, bradycardia, respiratory depression)	—

Countries

Japan

Contacts

Public ContactTakayoshi Nishimoto

Nippon Medical School Chiba-Hokuso Hospital Department of Gastroenterology

clubman629@nms.ac.jp0476-99-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026